Biogen Inc
BIIB181.940USD
-0.020-0.01%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
26.69BMarket Cap
16.59P/E TTM
More Details of Biogen Inc Company
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc Info
Ticker SymbolBIIB
Company nameBiogen Inc
IPO dateSep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Number of employees7605
Security typeOrdinary Share
Fiscal year-endSep 17
Address225 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone17814642000
Websitehttps://www.biogen.com/
Ticker SymbolBIIB
IPO dateSep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Company Executives of Biogen Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
Other
498.00M
18.82%
By RegionUSD
Name
Revenue
Proportion
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
Other
498.00M
18.82%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Other
64.59%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.19%
BlackRock Institutional Trust Company, N.A.
5.60%
State Street Investment Management (US)
4.99%
Wellington Management Company, LLP
2.89%
Other
64.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.44%
Investment Advisor/Hedge Fund
26.19%
Hedge Fund
8.03%
Pension Fund
2.94%
Research Firm
2.45%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.59%
Individual Investor
0.17%
Family Office
0.15%
Other
4.45%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
View more
Invesco Biotechnology & Genome ETF
Proportion5.03%
iShares Neuroscience and Healthcare ETF
Proportion4.13%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.82%
VanEck Biotech ETF
Proportion3.33%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.24%
Invesco Pharmaceuticals ETF
Proportion2.74%
First Trust Health Care Alphadex Fund
Proportion2.36%
Global X US Cash Flow Kings 100 ETF
Proportion2.26%
ProShares Ultra Nasdaq Biotechnology
Proportion2.12%
Invesco Nasdaq Biotechnology ETF
Proportion2.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biogen Inc?
The top five shareholders of Biogen Inc are:
The Vanguard Group, Inc. holds 17.21M shares, accounting for 11.74% of the total shares.
PRIMECAP Management Company holds 15.80M shares, accounting for 10.78% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.19M shares, accounting for 5.59% of the total shares.
State Street Investment Management (US) holds 7.47M shares, accounting for 5.09% of the total shares.
Wellington Management Company, LLP holds 4.80M shares, accounting for 3.27% of the total shares.
The Vanguard Group, Inc. holds 17.21M shares, accounting for 11.74% of the total shares.
PRIMECAP Management Company holds 15.80M shares, accounting for 10.78% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.19M shares, accounting for 5.59% of the total shares.
State Street Investment Management (US) holds 7.47M shares, accounting for 5.09% of the total shares.
Wellington Management Company, LLP holds 4.80M shares, accounting for 3.27% of the total shares.
What are the top three shareholder types of Biogen Inc?
The top three shareholder types of Biogen Inc are:
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Biogen Inc (BIIB)?
As of 2025Q3, 2020 institutions hold shares of Biogen Inc, with a combined market value of approximately 136.90M, accounting for 93.32% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.73%.
What is the biggest source of revenue for Biogen Inc?
In FY2025Q2, the MS product revenues-TYSABRI business generated the highest revenue for Biogen Inc, amounting to 839.80M and accounting for 31.74% of total revenue.
